Niva Bupa Q4 FY26 profit jumps 67% to ₹345 cr

Key takeaway from the March-quarter filing

Niva Bupa Health Insurance Company Ltd reported a strong rise in profitability in the March quarter, supported by higher income and premium growth. The standalone health insurer said net profit for the quarter rose 67% year on year to ₹345 crore, compared with ₹206 crore in the same period last year. Total income and gross written premium also increased, indicating continued traction in the retail health segment.

But the update also carried a key balance-sheet indicator to track. The company’s solvency ratio declined to 2.49 as on March 31, 2026, from 3.03 at the end of the fourth quarter of the previous fiscal year, as per the filing.

Q4 FY26: Profit climbs, income rises

For the March quarter, Niva Bupa said total income rose to ₹2,078 crore from ₹1,565 crore in the year-ago period. Total expenses increased to ₹1,795 crore from ₹1,470 crore, reflecting higher costs alongside growth. Despite the rise in expenses, the profit expansion suggests operating leverage during the quarter.

Gross written premium (GWP) increased to ₹2,880 crore in the quarter under review, compared with ₹2,079 crore in the same period a year ago. The company disclosed these details in a regulatory filing.

Solvency ratio declines to 2.49 as on March 31, 2026

Niva Bupa reported a solvency ratio of 2.49 as on March 31, 2026, lower than 3.03 at the end of the fourth quarter of the previous fiscal year. Solvency ratio is a closely watched metric in insurance because it indicates the insurer’s ability to meet long-term obligations.

The filing did not provide a detailed driver-by-driver explanation for the decline. Still, the disclosure sets a clear point for investors to monitor in subsequent quarters, especially alongside premium growth and claims performance.

Board approves elevation of Ankur Kharbanda

The company said its board has approved the elevation of Ankur Kharbanda to the position of executive director and deputy chief executive officer. Kharbanda is currently designated and serving as executive director and chief business officer.

The change is effective May 8, based on the recommendation of the nomination and remuneration committee, the company said.

FY26 operating indicators: claims and market share

Niva Bupa also highlighted customer and business metrics for FY26. The company reported a claim settlement ratio of 94.4% for FY26, an improvement of 205 basis points over the previous year.

In the retail health segment, it said market share improved to 10.1% at the close of FY26, representing a 76 basis points increase over FY25. These metrics matter because they frame growth quality, not just growth volume, in a category where customer experience and claims handling influence persistency and brand outcomes.

How this compares with FY25 disclosures

Earlier disclosures around FY25 provide context on the company’s growth trajectory. In its annual reporting for the year ended March 31, 2025, Niva Bupa reported gross written premium of ₹6,762 crore for the year, registering 21% growth over the previous year, with the solvency ratio stated at 303% (3.03) as on March 31, 2025 against a required solvency of 150%.

For FY25, the company reported net profit of ₹213.52 crore compared with ₹81.85 crore in the previous year, along with an underwriting loss of ₹249.8 crore versus ₹196.3 crore in the prior year. Separately, management commentary also referenced closing FY25 at GWP of ₹7,406 crore on a “without the 1/n accounting change” basis, and an IFRS profit after tax of ₹203.3 crore for the year.

Market reaction snapshot from Q4 FY25

Market reaction to results has previously been sharp. A separate market report on Q4 FY25 said Niva Bupa shares rose 13.39% to ₹91.88 on the NSE at 9:40 am on May 8 after the company released financial results for the March FY25 quarter.

While that move relates to FY25, it underlines how closely investors track premium growth and profitability for listed insurance names, and why quarterly disclosures on profit, solvency and claims experience can influence sentiment.

Summary table: Q4 FY26 vs year-ago quarter

Why the update matters for investors

The Q4 FY26 numbers show a combination of profit expansion and strong premium growth, both key drivers for valuation in the health insurance space. At the same time, the solvency ratio movement adds an important counterpoint because capital strength can shape growth flexibility, product strategy and regulatory comfort.

Operationally, the FY26 claim settlement ratio of 94.4% and the retail market share of 10.1% provide additional signals beyond the quarter, pointing to customer outcomes and competitive positioning. The management elevation effective May 8 is also notable because it clarifies leadership responsibilities as the company scales.

What to watch next

Investors will likely track whether premium growth sustains and how expenses behave relative to income in upcoming quarters. The solvency ratio trajectory will also be a key monitorable after the reported decline to 2.49 as on March 31, 2026.

The company has already communicated the leadership change effective May 8. The next set of regulatory filings and periodic updates should provide more colour on capital position, growth mix and claims experience as FY27 progresses.